BROCHURE REQUEST
IW Capital IW Capital
  • Home
  • About us
  • For Investors
  • For Financial Advisers
  • For Companies
  • Blogs
  • Contact Us
BROCHURE REQUEST
IW Capital

IW Capital completes Flarin funding round

6th November 2019
IW Capital completes Flarin funding round

IW Capital this week completed the first round of fund-raising for Flarin Holdings. Flarin Holdings was recently demerged from Infirst Healthcare Limited in order to provide greater focus on the rapid commercialisation of Flarin.

Flarin is a unique and patent protected lipid formulated ibuprofen which at a dose of 1200 mg/day has shown to be as effective as 2400mg/day of standard liquid ibuprofen capsules in patients with acute joint pain. Flarin’s unique lipid formulation also helps to shield the stomach from damage.

We are hugely excited to be involved with this innovative pharmaceutical product at an early stage in its commercial development. It is also key to be able to work with such an experienced management team in the pharmaceutical and healthcare arena.

Our research shows that around 20% of private investors are looking to invest within Pharma and Biotech while half of this group is put off by Big Pharma. With this in mind we were not surprised that the initial investment target for Flarin was over-subscribed by IW capital’s network of net-worth individuals and independent financial advisors.

There is a fantastic exit opportunity here with the product already fully developed and on sale in UK pharmacies, meaning there is already an established sales infrastructure in place.

“The very positive response we have had from presenting Flarin to new investors has given us great confidence in taking Flarin to the next stage of its commercial development,” says Andrew Macmillen, Managing Director. “These new funds give Flarin greater ability to increase investment in marketing in the UK as well as building a network of distributors and licensing partners in other countries.”

To find out more about IW Capital, or for more information on investment and non-executive opportunities, please speak to a member of the IW Capital team today on 020 7015 2250, or email info@iwcapital.co.uk

 

Archive

  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020

Related Posts

Over half of UK SMEs prioritise green energy for the rest of 2022

Over half of UK SMEs prioritise green energy for the rest of 2022

Levelling up: Small businesses use technology to overcome challenges

Levelling up: Small businesses use technology to overcome challenges

Investment announcement: We’re investing £8.7m in Rockwater Sandbanks & Branksome Ltd

Investment announcement: We’re investing £8.7m in Rockwater Sandbanks & Branksome Ltd

Consumer support reduces the risk of small business failure

Consumer support reduces the risk of small business failure

ADDRESS: IW Capital Ltd, 42 Bruton Place, London, W1J 6PA | TELEPHONE: +44(0)20 7015 2250 | EMAIL: info@iwcapital.co.uk

© 2022 IW Capital Ltd | T&Cs | Privacy Notice | Privacy Policy | Cookie Policy

IW Capital Ltd is an appointed representative of Bramdean Asset Management LLP, which is authorised and regulated in England by the Financial Conduct Authority under registration number: 410624.

IW Capital Ltd, 42 Bruton Place, London, W1J 6PA
+44(0)20 7015 2250
info@iwcapital.co.uk

© 2022 IW Capital Ltd | T&Cs | Privacy Notice | Privacy Policy | Cookie Policy

IW Capital Ltd is an appointed representative of Bramdean Asset Management LLP, which is authorised and regulated in England by the Financial Conduct Authority under registration number: 410624.

Copy